Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

1 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Krause, Stefan
VINCENT, NCT05904106 / 2021-003248-26: Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML	Recruiting	2	146	Europe	Venetoclax plus Azacitidine, standard of care chemotherapy plus gemtuzumab ozogamicin	Technische Universität Dresden, University Hospital Heidelberg, AbbVie	Acute Myeloid Leukemia	09/28	09/28